Article Text

PDF
A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations
  1. A Federico1,
  2. M Trappoliere1,
  3. C Tuccillo1,
  4. I de Sio1,
  5. A Di Leva1,
  6. C Del Vecchio Blanco1,
  7. C Loguercio1
  1. Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Naples, Italy
  1. Correspondence to:
    Professor C Loguercio
    Interuniversity Research Centre on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, 2nd University of Naples, Via Foria 58-80131 Naples, Italy; carmelina.loguercio{at}unina2.it

Statistics from Altmetric.com

Non-alcoholic fatty liver disease (NAFLD) may occur as an expression of a metabolic syndrome or in association with hepatitis C virus (HCV) chronic infection. The contemporaneous presence of NAFLD in this later group of patients may negatively affect the progression of fibrosis and the response to antiviral treatment.1,2 It has been suggested that in the future a therapeutic approach to chronic liver disease would consist of a number of complementary approaches considering the multitude of pathogenic mechanisms.3 Silybin is a natural flavonoid that has been conjugated to vitamin E and phospholipids to improve its bioavailability, and antioxidant and antifibrotic activity.4

After approval of the ethics committee and informed consent, 85 outpatients were consecutively enrolled in the study: 59 were affected by primitive NAFLD (group A) …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.